A petition urges the FDA to allow certain radiology AI software updates via postmarket study requirements instead of new 510(k) applications.
Key Details
- 1Petition submitted to the FDA seeks a streamlined pathway for radiology AI software with prior 510(k) clearance.
- 2Proposal targets CADx, CADe/x, CADt, and medical image analyzer software types under specified FDA regulations.
- 3Vendors with cleared devices could forgo new 510(k) submissions for new features, provided robust postmarket measures are in place.
- 4Existing 510(k) pathway would remain as an option; the new pathway would be partially exempt under defined conditions.
- 5FDA is accepting comments on the proposal until February 27, 2026.
- 6The proposal aims to close the 'innovation gap' between the U.S. and other regions, citing more limited AI diagnostic offerings in the U.S.
Why It Matters
If adopted, this pathway could accelerate the deployment of AI innovations in U.S. radiology by reducing regulatory redundancy, addressing concerns about lagging AI adoption compared to Europe. It signals ongoing regulatory evolution in medical imaging AI oversight.
Source
AuntMinnie
Related News
•HealthExec
AI Reimbursement, Biomedical Research, and Exec Survey Highlight Healthcare Trends
Healthcare AI adoption is rising, but ROI measurement and clinical impact remain key challenges.
•HealthExec
Senate Vote Fails to Block AI Medicare Prior Authorization Pilot
A Senate vote failed to halt the WISeR AI-based prior authorization pilot for traditional Medicare claims.
•AuntMinnie
Radiology Leads FDA AI Device Approvals Over Three Decades
Radiology accounts for 76% of all FDA-cleared AI/ML-enabled medical devices as of the end of 2025.